Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian M Jubb

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancerRoy S Herbst, S Gail Eckhardt, Razelle Kurzrock, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 13, 2011
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cellsChristy C Ong, Adrian M Jubb, Peter M Haverty, et al.
The Journal of Pathology|May 21, 2011
Notch3 signalling promotes tumour growth in colorectal cancerValentina Serafin, Luca Persano, Lidia Moserle, et al.
Cancer Research|September 18, 2012
p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer modelHoi Yee Chow, Adrian M Jubb, Jennifer N Koch, et al.
Journal of the National Cancer Institute|March 29, 2013
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanomaChristy C Ong, Adrian M Jubb, Diana Jakubiak, et al.
Plos One|March 8, 2013
High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neckDavid S Shames, Juliet Carbon, Kim Walter, et al.
The Journal of Experimental Medicine|October 30, 2013
Dual leucine zipper kinase is required for excitotoxicity-induced neuronal degenerationChristine D Pozniak, Arundhati Sengupta Ghosh, Alvin Gogineni, et al.
The Journal of Pathology|May 22, 2012
Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour modelsMallika Singh, Suzana S Couto, William F Forrest, et al.
The Journal of Pathology|July 31, 2014
PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibitionWei Zhou, Adrian M Jubb, Karen Lyle, et al.
The Journal of Clinical Investigation|August 16, 2013
Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacyLeisa Johnson, Mahrukh Huseni, Tanya Smyczek, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancerRoy S Herbst, S Gail Eckhardt, Razelle Kurzrock, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 13, 2011
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cellsChristy C Ong, Adrian M Jubb, Peter M Haverty, et al.
The Journal of Pathology|May 21, 2011
Notch3 signalling promotes tumour growth in colorectal cancerValentina Serafin, Luca Persano, Lidia Moserle, et al.
Cancer Research|September 18, 2012
p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer modelHoi Yee Chow, Adrian M Jubb, Jennifer N Koch, et al.
Journal of the National Cancer Institute|March 29, 2013
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanomaChristy C Ong, Adrian M Jubb, Diana Jakubiak, et al.
Plos One|March 8, 2013
High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neckDavid S Shames, Juliet Carbon, Kim Walter, et al.
The Journal of Experimental Medicine|October 30, 2013
Dual leucine zipper kinase is required for excitotoxicity-induced neuronal degenerationChristine D Pozniak, Arundhati Sengupta Ghosh, Alvin Gogineni, et al.
The Journal of Pathology|May 22, 2012
Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour modelsMallika Singh, Suzana S Couto, William F Forrest, et al.
The Journal of Pathology|July 31, 2014
PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibitionWei Zhou, Adrian M Jubb, Karen Lyle, et al.
The Journal of Clinical Investigation|August 16, 2013
Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacyLeisa Johnson, Mahrukh Huseni, Tanya Smyczek, et al.
Pageof 5